Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

April 11, 2023

Primary Completion Date

March 11, 2025

Study Completion Date

September 11, 2026

Conditions
Breast Cancer
Interventions
DRUG

Dalcelli、Exemestane、Gosserine

"Dalcelli: once a day, 125 mg each time, taken for 3 weeks, stopped for 1 week, 1 for 4 weeks~Period. It is recommended to take the medication at approximately the same time every day, delivered in warm water, on an empty stomach, at least before taking the medication~Fasting for 1 hour before and after.~Exemestane: 25mg, oral, once a day, continuous administration.~Gosserine: 3.6mg, subcutaneous injection, once every four weeks, continuous administration"

DRUG

Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection

"Docetaxel for injection: 75mg/m2, intravenous drip, approximately 30 minutes. Dose reduction and delayed administration are allowed every three weeks, with a maximum of three weeks of delayed administration allowed since the last administration time~Calculate, otherwise terminate treatment.~5\. Epirubicin hydrochloride for injection: 75mg/m2, intravenous drip. Once every three weeks, allowing for dose reduction~And delayed administration, with a maximum allowable delay of 3 weeks, calculated from the last administration time. Otherwise~Stop treatment.~6\. Cyclophosphamide for injection: 500mg/m2, intravenous drip. Once every three weeks, allowing for dose reduction and~Delayed administration, allowed up to 3 weeks, calculated from the last administration time, otherwise terminated treat"

Trial Locations (1)

300000

RECRUITING

Jie Ge, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER